The global liquid biopsy market size valued US$ 891.076 million in 2020 and expected to reach US$ 2846.83 million by 2026, at CAGR of 21.6% during forecast period 2020-2026. The market is gaining traction in recent times owing to its accurate, effective results in comparison with traditional cancer screening methods, which are achieved through minimal invasiveness and expenses. Challenges associated with traditional biopsies such as invasiveness, ill-informed results, post-sampling medical challenges and costs are prompting the healthcare professionals to adopt less invasive liquid biopsy tests for cancer screening and management, which is projected to create significant market demand for liquid biopsy products and services over the forecast period. Moreover, several clinical research activities related to biomarkers are in late stage and it is expected that upon successful launch and commercialization of these tests over the forecast period will result in significant market growth. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, This report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed liquid biopsy market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities).